Literature DB >> 29120834

Cervical cancer screening in the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) in four US-Affiliated Pacific Islands between 2007 and 2015.

Virginia Senkomago1, Janet Royalty2, Jacqueline W Miller2, Lee E Buenconsejo-Lum3, Vicki B Benard2, Mona Saraiya2.   

Abstract

BACKGROUND: Cervical cancer incidence in the US-Affiliated Pacific Islands (USAPIs) is double that of the US mainland. American Samoa, Commonwealth of Northern Mariana Islands (CNMI), Guam and the Republic of Palau receive funding from the Centers for Disease Control (CDC) National Breast and Cervical Cancer Early Detection Program (NBCCEDP) to implement cervical cancer screening to low-income, uninsured or under insured women. The USAPI grantees report data on screening and follow-up activities to the CDC.
MATERIALS AND METHODS: We examined cervical cancer screening and follow-up data from the NBCCEDP programs in the four USAPIs from 2007 to 2015. We summarized screening done by Papanicolaou (Pap) and oncogenic human papillomavirus (HPV) tests, follow-up and diagnostic tests provided, and histology results observed.
RESULTS: A total of 22,249 Pap tests were conducted in 14,206 women in the four USAPIs programs from 2007-2015. The overall percentages of abnormal Pap results (low-grade squamous intraepithelial lesions or worse) was 2.4% for first program screens and 1.8% for subsequent program screens. Histology results showed a high proportion of cervical intraepithelial neoplasia grade 2 or worse (57%) among women with precancers and cancers. Roughly one-third (32%) of Pap test results warranting follow-up had no data recorded on diagnostic tests or follow-up done.
CONCLUSION: This is the first report of cervical cancer screening and outcomes of women served in the USAPI through the NBCCEDP with similar results for abnormal Pap tests, but higher proportion of precancers and cancers, when compared to national NBCCEDP data. The USAPI face significant challenges in implementing cervical cancer screening, particularly in providing and recording data on diagnostic tests and follow-up. The screening programs in the USAPI should further examine specific barriers to follow-up of women with abnormal Pap results and possible solutions to address them. Published by Elsevier Ltd.

Entities:  

Keywords:  Cervical cancer; NBCCEDP; Screening; US territories; US-Affiliated Pacific Islands

Mesh:

Year:  2017        PMID: 29120834      PMCID: PMC5739878          DOI: 10.1016/j.canep.2017.04.011

Source DB:  PubMed          Journal:  Cancer Epidemiol        ISSN: 1877-7821            Impact factor:   2.984


  13 in total

1.  Screening for cervical cancer: recommendations and rationale.

Authors: 
Journal:  Am J Nurs       Date:  2003-11       Impact factor: 2.220

2.  2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors.

Authors:  L Stewart Massad; Mark H Einstein; Warner K Huh; Hormuzd A Katki; Walter K Kinney; Mark Schiffman; Diane Solomon; Nicolas Wentzensen; Herschel W Lawson
Journal:  Obstet Gynecol       Date:  2013-04       Impact factor: 7.661

Review 3.  Human papillomavirus infection and the multistage carcinogenesis of cervical cancer.

Authors:  Mark Schiffman; Nicolas Wentzensen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-04       Impact factor: 4.254

Review 4.  The 2001 Bethesda System: terminology for reporting results of cervical cytology.

Authors:  Diane Solomon; Diane Davey; Robert Kurman; Ann Moriarty; Dennis O'Connor; Marianne Prey; Stephen Raab; Mark Sherman; David Wilbur; Thomas Wright; Nancy Young
Journal:  JAMA       Date:  2002-04-24       Impact factor: 56.272

5.  National Breast and Cervical Cancer Early Detection Program data validation project.

Authors:  Christie R Eheman; Steven Leadbetter; Vicki B Benard; A Blythe Ryerson; Janet E Royalty; Donald Blackman; Lori A Pollack; Paula Willey Adams; Fran Babcock
Journal:  Cancer       Date:  2014-08-15       Impact factor: 6.860

6.  Implementation of the National Breast and Cervical Cancer Early Detection Program: the beginning.

Authors:  Nancy C Lee; Faye L Wong; Patricia M Jamison; Sandra F Jones; Louise Galaska; Kevin T Brady; Barbara Wethers; George-Ann Stokes-Townsend
Journal:  Cancer       Date:  2014-08-15       Impact factor: 6.860

7.  Cervical screening in the National Breast and Cervical Cancer Early Detection Program, 1995-2001.

Authors:  Vicki B Benard; Christie R Eheman; Herschel W Lawson; Donald K Blackman; Christa Anderson; William Helsel; Sandra F Thames; Nancy C Lee
Journal:  Obstet Gynecol       Date:  2004-03       Impact factor: 7.661

8.  Cervical Cancer Screening in the United States-Affiliated Pacific Islands: Options and Opportunities.

Authors:  Alan G Waxman; Lee E Buenconsejo-Lum; Miriam Cremer; Sarah Feldman; Kevin A Ault; Joanna M Cain; Maria Lina Diaz
Journal:  J Low Genit Tract Dis       Date:  2016-01       Impact factor: 1.925

9.  Current cervical cancer screening knowledge, awareness, and practices among U.S. affiliated pacific island providers: opportunities and challenges.

Authors:  Julie S Townsend; Analía Romina Stormo; Katherine B Roland; Lee Buenconsejo-Lum; Susan White; Mona Saraiya
Journal:  Oncologist       Date:  2014-03-25

10.  Vital signs: cervical cancer incidence, mortality, and screening - United States, 2007-2012.

Authors:  Vicki B Benard; Cheryll C Thomas; Jessica King; Greta M Massetti; V Paul Doria-Rose; Mona Saraiya
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2014-11-07       Impact factor: 17.586

View more
  2 in total

1.  Together we can: Collaborative Efforts to Reduce the Cancer Burden on Guam and Save Lives.

Authors:  Renata A Bordallo; Lawrence Alam; Arlie Bonto; Alyssa Uncangco; Lee Buenconsejo-Lum
Journal:  Guam Med Assoc J       Date:  2019-03

2.  The artificial intelligence-assisted cytology diagnostic system in large-scale cervical cancer screening: A population-based cohort study of 0.7 million women.

Authors:  Heling Bao; Xiaorong Sun; Yi Zhang; Baochuan Pang; Hua Li; Liang Zhou; Fengpin Wu; Dehua Cao; Jian Wang; Bojana Turic; Linhong Wang
Journal:  Cancer Med       Date:  2020-07-22       Impact factor: 4.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.